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Background  and  purpose:  There  are  few  data  that  demonstrate  a signiﬁcant  effect  of  aspirin  therapy  for
diabetic patients  as  primary  prevention  for cardiovascular  events.  A guideline  recommends  the  use  of
aspirin  as  a primary  prevention  strategy  in  patients  with  diabetes  who  are  at increased  cardiovascular
risk  including  those  who  have  additional  risk  factors.  To  clarify  the  effect  of  primary  prevention  with
aspirin  therapy  on diabetic  patients,  the  relationship  between  C-reactive  protein  (CRP)  and  the  inci-
dence  of atherosclerotic  events  was  investigated  in participants  in  the Japanese  primary  prevention  of
atherosclerosis  with  aspirin  for diabetes  (JPAD)  trial.
Methods  and subjects:  We  divided  the  JPAD  participants  according  to  the  CRP  level  at  enrollment;
CRP  ≥  0.1 mg/dl:  high  CRP  group,  CRP  <  0.1  mg/dl:  low  CRP group.  The  high  CRP  group  consisted  of  1131
patients  and  the low  CRP  group  consisted  of  398  patients.
Essential  results:  There  was no signiﬁcant  difference  in  the  incidence  of  primary  atherosclerotic  events
between  the  high  CRP  group  and  the low  CRP  group.  Of the atherosclerotic  events,  the incidence  of
cerebrovascular  events,  however,  was  signiﬁcantly  higher  in  the  high  CRP  group  than  in  the  low  CRP
group.  The  incidence  of  cerebrovascular  events  was  higher  in  the  high  CRP  group  than  in  the  low  CRP
group  in patients  without  aspirin  therapy,  although  there  was  no  signiﬁcant  difference  in the incidence
of  the  cerebrovascular  events  between  the  high  CRP  group  and  the  low  CRP  group  in patients  undergoing
aspirin  therapy.
irin  thPrincipal  conclusions:  Asp
CRP.  Aspirin  therapy  could  be
higher  CRP.
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IntroductionIt has been reported that atherosclerosis is the results of sev-
eral pathogenic factors including inﬂammatory changes [1] and
increased levels of inﬂammatory markers such as C-reactive pro-
tein (CRP) may  reﬂect vascular complications and predict future
vier Ltd. All rights reserved.
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vents [2–6]. Diabetes mellitus is also a powerful risk factor
or cardiovascular events [7–13]. The American Diabetes Asso-
iation recommends the use of aspirin as a primary prevention
trategy in patients with diabetes who are at increased cardio-
ascular risk, including those who are older than 50 years or
ho have additional risk factors [14]. However, there are few
eports that demonstrate a signiﬁcant effect of aspirin therapy
or diabetic patients as a primary prevention for cardiovascular
vents. A previous meta-analysis (287 trials, 135,000 participants)
n the efﬁcacy of antiplatelet therapy in the prevention of major
ardiovascular events found a clear beneﬁt for aspirin, but no sta-
istically signiﬁcant beneﬁt in the subgroup of only people with
iabetes (9 trials, 5126 participants) [15]. No signiﬁcant reduction
n the risk of major cardiovascular events with low-dose aspirin
ompared with placebo was found in two trials published after
he above-mentioned meta-analysis [16,17]. We  undertook the
apanese primary prevention of atherosclerosis with aspirin for
iabetes (JPAD) trial to examine the efﬁcacy of low-dose aspirin
herapy for the primary prevention of atherosclerotic events in type
 diabetic patients [18]. A clear beneﬁt for aspirin in the primary
revention of major cardiovascular events in patients with diabetes
emains to be elucidated [18,19]. Therefore, we sought to inves-
igate whether aspirin therapy was effective for diabetic patients
ith higher CRP levels.
aterials and methods
The JPAD trial design and overall ﬁndings have been reported
reviously [18]. The study protocol is in agreement with the
uidelines of the ethics committees at our institutions and the
tudy complies with the 1975 Declaration of Helsinki. Brieﬂy,
his multicenter, prospective, randomized, open, blinded end-point
tudy was conducted at 163 institutions throughout Japan, which
nrolled 2539 patients with type 2 diabetes, without a history
f atherosclerotic disease. The institutional review board at each
articipating hospital approved this trial, and written informed
onsent was obtained from each patient. In the JPAD trial, the inclu-
ion criteria were diagnosis of type 2 diabetes mellitus, age between
0 and 85 years, and ability to provide informed consent. The exclu-
ion criteria were electrocardiographic ischemic changes, a history
f coronary heart disease, cerebrovascular disease, arteriosclerotic
isease, atrial ﬁbrillation, use of antiplatelet or antithrombotic ther-
py, a history of severe gastric or duodenal ulcer, severe liver
ysfunction, severe renal dysfunction, and allergy to aspirin [18].
 total of 2539 patients were randomly assigned as follows: 1262
atients in the aspirin group; and 1277 patients in the nonaspirin
roup. The median follow-up period was 4.37 years.
It was reported in the Women’s Health Study that median CRP
evel in Asians was 0.112 mg/dl and that this value was lower
han that in black women, Hispanic women, and white women
20]. A recent Japanese study also used a CRP level of 0.1 mg/dl
o stratify the patients [21]. In this subanalysis, therefore, we
ivided the JPAD participants according to the CRP levels at enroll-
ent (CRP ≥ 0.1 mg/dl, High CRP group; CRP < 0.1 mg/dl, Low CRP
roup). The high CRP group consisted of 1131 patients and the low
RP group consisted of 398 patients. We  conducted atheroscle-
otic events analyses and subgroup analyses of atherosclerotic
vents: cerebrovascular events, including stroke and transient
schemic attack; coronary events, including myocardial infarction
nd angina; and, aortic and peripheral vascular events.
eﬁnition of atherosclerotic eventThe primary end point was any atherosclerotic event, which was
 composite of sudden death; death from coronary, cerebrovas-
ular, and aortic causes; nonfatal acute myocardial infarction;iology 62 (2013) 165–170
unstable angina; newly developed exertional angina; nonfatal
ischemic and hemorrhagic stroke; transient ischemic attack; or
nonfatal aortic and peripheral vascular disease (arteriosclerosis
obliterans, aortic dissection, mesenteric arterial thrombosis) dur-
ing the follow-up period. All potential end points were adjudicated
by an independent committee on validation of data and events that
were unaware of the group assignments.
Presentation of hemoglobin A1c level
Hemoglobin A1c values were converted from the Japanese Dia-
betes Society (JDS) values used in the main analysis of the JPAD trial
into National Glycoprotein Standardization Program (NGSP) equiv-
alent values. NGSP equivalent values were calculated using the
following formula: NGSP equivalent value (%) = JDS value (%) + 0.4%
[22].
Statistical analyses
Efﬁcacy comparisons were performed on the basis of time to the
ﬁrst event, according to the intention-to-treat principle, including
all patients in each group to which they were randomized with
patients lost to follow-up cut from the study as of their last hospi-
tal visit. Following the descriptive statistics, cumulative incidences
of primary end points were estimated utilizing the Kaplan–Meier
method and differences between groups were then assessed with
the log-rank test. The chi-square test was used to compare the
frequency data between the groups. We  used the Cox propor-
tional hazards analysis to estimate hazards ratios (HRs) of CRP
level (CRP ≥ 0.1 mg/dl), with 95% CI. We included the clinically
signiﬁcant factors such as age [18], aspirin [18], CRP, hyperten-
sion [23], 90 ml/min/1.73 m2 > estimated glomerular ﬁltration rate
(eGFR) ≥ 60 ml/min/1.73 m2 [24], and 60 ml/min/1.73 m2 > eGFR
[23]. Patients with missing values for any selected variable were
excluded from the analyses that used this variable. All statistical
analyses were conducted using SAS software Version 9.1 (SAS Insti-
tute Inc, Cary, NC, USA). p-Values of less than 0.05 were considered
statistically signiﬁcant.
Results
Baseline clinical characteristics
The baseline clinical patient characteristics are shown in Table 1.
There were signiﬁcant differences in body mass index, the fre-
quency of diabetic neuropathy, and proteinuria between the high
CRP group and the low CRP group. The use of calcium channel block-
ers and -blockers were signiﬁcantly higher in the high CRP group
than low CRP group. The clinical characteristics, such as age, gender,
BP, the frequency of smoking, dyslipidemia, diabetic retinopathy,
diabetic nephropathy, duration of diabetes, use of statins, and use
of drugs for diabetes except for the usage of biguanides, were all
similar between the high CRP group and the low CRP group.
High CRP is not a risk for atherosclerotic events in diabetic patients
There was  no signiﬁcant difference in the incidence of the pri-
mary atherosclerotic events between the high CRP group and the
low CRP group (HR, 1.31; 95% CI, 0.83–2.15; log-rank test, p = 0.26).
Subgroup analyses of cerebrovascular events, coronary events,
and aortic and peripheral vascular eventsThe atherosclerotic events are shown in Table 2. The occurrence
and incidence rates of cerebrovascular events was signiﬁcantly
higher in the high CRP group (44 events, 3.9%) than in the low
CRP group (7 events, 1.8%) (HR, 2.29; 95% CI, 1.10–5.57; log-rank
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Table  1
Baseline characteristics.
Characteristics High CRP group (n = 1139) Low CRP group (n = 398) p-Value
Age (years) 65 ± 10 64 ± 10 0.1
Male  620 (55) 222 (56) 0.7
Systolic blood pressure (mmHg) 135 ± 15 134 ± 16 0.3
Diastolic blood pressure (mmHg) 77 ± 9 76 ± 9 0.2
Body  mass index (kg/m2) 25 ± 4 24 ± 3 0.0007
Current smoker 253 (22) 88 (22) 0.9
Past  smoker 475 (42) 167 (42) 0.98
Dyslipidemia 600 (53) 213 (54) 0.9
Duration of diabetes, median, 2397 2427 0.6
IQR  (days) 1017–4539 984–4162
Diabetic retinopathy 153 (14) 57 (14) 0.7
Diabetic nephropathy 139 (12) 58 (15) 0.2
Proteinuria 219 (20) 59 (15) 0.04
Diabetic neuropathy 112 (10) 62 (16) 0.002
Dermal ulcer 3 (0.3) 4 (1.0) 0.08
Atrial  ﬁbrillation 2 (0.2) 1 (0.3) 1
Treatment for hypertension
Calcium channel blockers 403 (36) 118 (30) 0.03
Angiotensin-II receptor blockers 227 (20) 72 (18) 0.4
Angiotensin-converting enzyme inhibitors 165 (15) 47 (12) 0.2
-Blockers 97 (9) 18 (5) 0.008
-Blockers 49 (4) 12 (3) 0.2
Treatment for diabetes and dyslipidemia
Sulfonylureas 662 (59) 233 (59) 0.5
-Glucosidase inhibitors 392 (35) 126 (32) 0.3
Biguanides 138 (12) 70 (18) 0.007
Insulin 151 (13) 40 (10) 0.09
Thiazolidines 51 (5) 24 (6) 0.2
Statins 229 (26) 112 (28) 0.5
Family history
Ischemic heart disease 116 (11) 174 (11) 0.9
Stroke 201 (20) 325 (21) 0.3
Hemoglobin A1c level (%) 7.1 ± 1.4 6.8 ± 1.0 <0.0001
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between the high CRP group and the low CRP group (HR, 1.54; 95%
CI, 0.63–4.64; log-rank test, p = 0.3817, Fig. 2 Bottom) in patients
receiving aspirin therapy.Fasting plasma glucose level (mg/dl) 147 ± 52 
ata are mean ± SD or n (%). CRP, C-reactive protein; IQR, interquartile range.
est, p = 0.0361, Table 2, Fig. 1). Ischemic stroke happened in 29
atients of the high CRP group and in 4 patients of the low group,
nd hemorrhagic stroke happened in 8 patients of the high CRP
roup and in 1 patient of the low CRP group. The incidence rate of
schemic stroke events tended to be higher in the high CRP group
han in the low CRP group (HR, 2.64; 95% CI, 1.04–8.91; log-rank
est, p = 0.0583). There were no signiﬁcant differences, however,
n the occurrence rate of coronary events between the high CRP
roup (2.4%) and the low CRP group (3.5%, Table 2). There was  no
igniﬁcant difference in the occurrence rate of aortic and periph-
ral vascular events between the high CRP group (0.3%) and the low
RP group (0.7%, Table 2). Cox proportional hazards analysis includ-
ng clinically important factors revealed that age and hypertension
ere independent predictive factors for cerebrovascular events in
ype 2 diabetic patients (Table 3). And, CRP was also an impor-
ant predictive factor for cerebrovascular events in type 2 diabetic
atients.
able 2
therosclerotic events.
High CRP group
(n = 1131)
Low CRP group
(n = 398)
p-Value
Coronary events 27 (2.4) 14 (3.5) 0.2
Cerebrovascular events 44 (3.9) 7 (1.8) 0.04
Aortic and peripheral vascular
events
8 (0.7) 1 (0.3) 0.5
Death from coronary events 3 (0.3) 0 (0) 0.8
Death from cerebrovascular
events
4 (0.3) 1 (0.3) 1
All  deaths 28 (2.5) 8 (2.0) 0.6
ata are n (%), CRP, C-reactive protein.140 ± 36 0.003
Effect of aspirin therapy on the incidence of cerebrovascular events
We compared the incidence of cerebrovascular events between
the patients receiving aspirin therapy and those not receiving
aspirin therapy. The incidence of cerebrovascular events was sig-
niﬁcantly higher in the high CRP group than in the low CRP group
(HR, 4.12; 95% CI, 1.22–25.6424; log-rank test, p = 0.0367, Fig. 2 Top)
in patients not receiving aspirin therapy; there was no signiﬁcant
difference, however, in the incidence rate of cerebrovascular eventsFig. 1. Comparison of cerebrovascular events between the high C-reactive protein
(CRP) group and the low CRP group. The incidence of cerebrovascular events was
signiﬁcantly higher in the high CRP group than in the low CRP group.
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Table 3
Multivariate Cox proportional hazards model for cerebrovascular events.
Factor Hazard ratio 95% CI p-Value
High CRP (CRP ≥ 0.1 mg/dl) 2.21 0.99–4.91 0.052
Use  of aspirin 0.92 0.53–1.60 0.789
Age ≥ 65 (years) 2.13 1.14–3.99 0.018
Blood  pressure control (SBP ≥ 140 mmHg  and/or DBP ≥ 90 mmHg) 2.24 1.28–3.91 0.005
90  (ml/min/1.73 m2) > eGFR ≥ 60 (ml/min/1.73 m2) 2.26 0.87–5.86 0.092
60  (ml/min/1.73 m2) > eGFR 1.79 0.63–5.07 0.271
C  eGFR
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iscussion
In the present study, although the incidence of primary
therosclerotic events in type 2 diabetics, consisting of cerebrovas-
ular events, coronary events, and aortic or peripheral vascular
vents, was not signiﬁcantly different between the high CRP group
nd the low CRP group, the incidence of cerebrovascular events
as signiﬁcantly higher in the high CRP group than in the low CRP
roup. It indicates that CRP may  inﬂuence the incidence of primary
erebrovascular event in diabetic patients.
Recently, the Antithrombotic Trialists’ (ATT) Collaboration
ndertook a meta-analysis that compared long-term aspirin use
ersus a non-aspirin control. The meta-analysis result that aspirin
herapy yielded a 12% proportional reduction in serious vascular
vents in the primary prevention trials was reported [25]. How-
ver, this study included a small number of diabetic patients. Then,
he data do not support the effect of aspirin therapy in the pri-
ary prevention of major cardiovascular events in patients with
iabetes.
ig. 2. (Top) Comparison of cerebrovascular events between the high C-reactive
rotein (CRP) group and the low CRP group without aspirin therapy. The incidence
ate of cerebrovascular events was signiﬁcantly higher in the high CRP group than in
he  low CRP group in patients not receiving aspirin therapy. (Bottom) Comparison
f cerebrovascular events between the high CRP group and the low CRP group with
spirin therapy. The incidence rate of the cerebrovascular events in the high CRP
roup was as low as the incidence of the low CRP group in patients receiving aspirin
herapy., estimated glomerular ﬁltration rate.
In the present study, we performed Cox proportional hazards
analysis including signiﬁcant predictive factors because we previ-
ously showed signiﬁcant effect of age, aspirin, hypertension, and
eGFR on the incidence of atherosclerotic events in diabetic patients
[18,23,24]. The Cox proportional hazards analysis revealed that
higher CRP level is not an independent but important predictive
factor for cerebrovascular events in type 2 diabetic patients. The
incidence of cerebrovascular events was signiﬁcantly higher in the
high CRP group than in the low CRP group in patients without
aspirin therapy, although there was  no signiﬁcant difference in the
incidence of cerebrovascular events between the high CRP group
and the low CRP group in patients with aspirin therapy. It indicates
that aspirin therapy may  reduce the incidence of cerebrovascular
events only in patients with higher CRP level. On the other hand,
Cox proportional hazards analysis showed that aspirin is not an
independent predictive factor for cerebrovascular events. There-
fore, the present study shows the possibility that aspirin reduces
cerebrovascular events in diabetic patients with higher CRP levels.
To demonstrate the signiﬁcance of aspirin therapy, we  may  need a
more appropriate control group.
The possible mechanism for the beneﬁcial effect of aspirin
therapy on the prevention of cerebrovascular events is inhibi-
tion of thrombus formation via blocking thromboxane dependent
platelet activation. Elevated CRP levels may  reﬂect the existence of
advanced atherosclerosis induced by other cardiovascular risk fac-
tors because inﬂammation is strongly related to atherosclerosis. It
is thought that the coexistence of elevated CRP level and other risk
factors is a marker of a group at high risk of atherosclerosis, and,
thus, the risk of cerebrovascular events is remarkably high in that
group. Additionally, recent clinical reviews, as well as experimen-
tal and clinical studies, have shown that inﬂammation is directly
associated with the development of atherosclerosis [1] and insta-
bility of atheroma [26,27]. It is, therefore, speculated that chronic
inﬂammation directly and extremely enhances the risk of cere-
brovascular events by such atherogenic effects of inﬂammation in
people whose arterial walls have already been damaged by other
risk factors and aspirin therapy possibly reduces cerebrovascular
events.
In the present study, aspirin therapy did not reduce aortic
and peripheral vascular events. There are only a few reports that
describe the association between aortic and peripheral vascular
events and aspirin therapy in diabetic patients. Aspirin therapy
did not show any signiﬁcant preventive effect for cardiovascular
events in asymptomatic diabetic patients with lower ankle brachial
pressure indexes in the POPADAD Trial [17].
As regards the incidence of coronary events, there were no sig-
niﬁcant differences between the high CRP group and the low CRP
group. This is because the incidence of myocardial infarction was
higher in the high CRP group than in the low CRP group, but the
incidence of angina was higher in the low CRP group than in the
high CRP group. Thus, the inﬂuence of higher CRP on the incidence
of coronary events appears to be stronger in cases of serious coro-
nary events than in all coronary events. This may  be associated with
the report that acetylcholine induces coronary spasm and ischemic
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ymptoms were more frequent in aspirin users than in non-users
28].
tudy limitations
This subanalysis has a few limitations in addition to those
eported in the JPAD Study [18]. The JPAD trial did not achieve the
lanned statistical power due to the lower incidence of atheroscle-
otic events than that expected. Because the present study was  a
ubanalysis of the JPAD trial, the number of patients and number of
vents was lower than the main study. Therefore, the present study
s much more underpowered to see the effects of aspirin in the
elected subgroups. Thus, a new trial which sets diabetic patients
ith higher CRP level as the main object is needed.
In conclusion, this study indicates that CRP level inﬂuences the
ncidence of cerebrovascular events in diabetic patients. In the pri-
ary prevention of cerebrovascular events, aspirin therapy might
ave an effect on diabetic patients with higher CRP.
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